Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Maes

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 19, 2004
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT StudyAlan G Jardine, Hallvard Holdaas, Bengt Fellström, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment responseInge Derdelinckx, Kristel Van Laethem, Bart Maes, et al.
Kidney International|October 2, 2004
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
Lancet (London, England)|June 20, 2003
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Clinical Kidney Journal|June 27, 2022
Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registryWim Laurens, Dries Deleersnijder, Amélie Dendooven, et al.
Antiviral Chemistry & Chemotherapy|December 24, 2002
A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failureKristien Van Vaerenbergh, Sabina De Geest, Inge Derdelinckx, et al.
Clinical Kidney Journal|February 2, 2023
Clinicopathological characteristics and disease chronicity in native kidney biopsies in FlandersDries Deleersnijder, Wim Laurens, Johan De Meester, et al.
The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.
The New England Journal of Medicine|March 30, 2026
Iptacopan in IgA Nephropathy - Final 24-Month DataJonathan Barratt, Necmi Eren, Naoki Kashihara, et al.
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 19, 2004
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT StudyAlan G Jardine, Hallvard Holdaas, Bengt Fellström, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment responseInge Derdelinckx, Kristel Van Laethem, Bart Maes, et al.
Kidney International|October 2, 2004
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
Lancet (London, England)|June 20, 2003
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Clinical Kidney Journal|June 27, 2022
Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registryWim Laurens, Dries Deleersnijder, Amélie Dendooven, et al.
Antiviral Chemistry & Chemotherapy|December 24, 2002
A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failureKristien Van Vaerenbergh, Sabina De Geest, Inge Derdelinckx, et al.
Clinical Kidney Journal|February 2, 2023
Clinicopathological characteristics and disease chronicity in native kidney biopsies in FlandersDries Deleersnijder, Wim Laurens, Johan De Meester, et al.
The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.
The New England Journal of Medicine|March 30, 2026
Iptacopan in IgA Nephropathy - Final 24-Month DataJonathan Barratt, Necmi Eren, Naoki Kashihara, et al.
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Pageof 8